Notizie

Più notizie

  • 17.05.2021

    Impact investing: reconciling nature and our finances

    Raconteur (The Wealth Management 2021 report published in The Sunday Times - 16.05.2021) - The health of our planet is intimately linked to your pension and your long-term financial goals, says Victoria Leggett, Head of Impact Investing at UBP.

  • 12.05.2021

    No sharp rate rises on the Fed’s watch

    Finanz und Wirtschaft (19.01.2021) - Norman Villamin, Chief Investment Officer Wealth Management of Union Bancaire Privée, considers fears of significantly higher interest rates to be premature. He prefers mining to banking stocks.

  • 07.05.2021

    Positioning for rising real rates over the medium term

    Institutional Money (06.05.2021) - In recent months, nominal interest rates have increased globally. While this trend is expected to continue, the drivers of this move are likely to change, thereby affecting how investors position themselves in fixed-income markets.

  • 06.05.2021

    Why the Japanese market is performing well again

    Japan’s equity markets have outpaced other major developed market equities in both 2020 and year-to-date in 2021 as the world seeks to transition to a post-pandemic recovery.

  • 05.05.2021

    UBP’s wealth management model in Asia

    Hubbis (03.04.2021) – Hubbis recently spoke with Michael Blake, CEO UBP Asia, as he cast his eye over the regional wealth management market and explained why he and UBP remain so optimistic about private banking in the region.

  • 19.04.2021

    Is an integrated model key to serving familyoffices?

    PWM (08.04.2021) – Union Bancaire Privée’s Michael Blake discusses the importance of an integrated investment banking and wealth management model for servicing wealthy families

  • 14.04.2021

    The vaccine disrupting the pharma industry

    UBP talks to Stéphane Bancel, Moderna CEO, to learn how the mRNA technology not only made one of the first COVID-19 vaccines possible, but, more importantly for investors, has the potential to disrupt the broader pharmaceutical industry in its wake.

Our latest podcasts

Our latest podcasts

Iscrivetevi alle nostre newsletter